Cite
HARVARD Citation
Fromm, G. et al. (2018). Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy. Journal for immunotherapy of cancer. 6 (1), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Fromm, G. et al. (2018). Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy. Journal for immunotherapy of cancer. 6 (1), p. . [Online].